GRM5 and Cognitive impairment: Preclinical studies suggest that mGluR5 agonists or PAMs enhance NMDAR function and mitigate cognitive deficits in SCZ models [146, 147] (Table 1), highlighting mGluR5 as a promising therapeutic target.